TORONTO (PRWEB) October 22, 2019
Tumor biopsies from all three tumor types were collected i) prior to treatment, ii) after 12 weeks of nivolumab monotherapy and iii) after completion of NEO-PV-01 vaccination. Targeted gene expression analysis on RNA extracted from FFPE blocks was performed using the Research Use Only NanoString® nCounter® platform. A Custom CodeSet of 800 genes included markers for immune cell populations, cytolytic markers, immune activation and suppression and the tumor microenvironment. Gene signatures of key immune features were calculated after normalization with housekeeping genes and used for subsequent analysis.
Neoantigens arise from DNA mutations in cancer cells and are important targets for T cell-mediated anti-tumor immunity. NEO-PV-01 is a personal neoantigen vaccine of up to 20 peptides designed based on a patient’s neoantigen and HLA profile that is directed at inducing tumor-specific T cell responses to neoantigens. There is a wealth of data to extract from a comprehensive gene expression analysis of the tumor microenvironment in patients with advanced cancer given a combination of neoantigen vaccine and checkpoint inhibitor immunotherapy.
Join industry expert Meghan Bushway, Senior Scientist, Translational Immunology, Neon Therapeutics for a live webinar on Wednesday, November 6, 2019 at 12pm EST (5pm GMT). A Q&A with the audience will be included.
For more information or to register for this event, visit The Impact of Neoantigen Vaccine & Nivolumab Treatment on the Tumor Microenvironment.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.